Holy Cross Health is raising the bar in cancer care by introducing bispecific antibody therapy—a groundbreaking treatment now offered through the Michael and Dianne Bienes Comprehensive Cancer Center. This innovative therapy represents a significant shift in how certain cancers are treated, and nurses are central to its safe and successful delivery.
Bispecific antibodies are designed to enhance the immune response by acting as matchmakers between cancer cells and T-cells. This connection enables the immune system to target and destroy malignant cells directly. This dual-targeting approach has shown significant promise in treating multiple myeloma, lymphoma, and small cell lung cancer, particularly when standard treatments are ineffective.
“We are excited to bring this cutting-edge therapy to our patients at Holy Cross Health. Our team has undergone extensive preparation to ensure we are fully equipped to deliver this treatment safely and effectively,” said Simon Blanc, M.D., Hematologist/Oncologist. “This represents a major step forward in our ability to fight cancer and improve outcomes for our patients.”
Watch Dr. Blanc explaining bispecific therapy and its clinical application in this video.
For oncology nurses, bispecific therapy means new protocols, advanced monitoring, and expanded clinical knowledge—particularly around managing cytokine release syndrome (CRS) and neurotoxicities, which are potential side effects. To mitigate risks, patients begin therapy under hospital observation through a step-up dosing schedule, allowing nurses to monitor early response and intervene quickly if needed closely.
As frontline providers, nurses are instrumental in educating patients, administering treatment, recognizing early signs of complications, and transitioning patients to outpatient maintenance therapy. For those transferring from other facilities, the Holy Cross Health Bispecific Maintenance Therapy Program ensures seamless care continuity—supported by expert clinicians and compassionate, well-trained nursing staff.
By adopting bispecific antibody therapy, Holy Cross Health is expanding its oncology capabilities and empowering its nursing team with cutting-edge tools to drive better patient outcomes locally and accessibly.
For scheduling and more details, visit holy-cross.com
.
The post Holy Cross Health Empowers Nurses with Cutting-Edge Cancer Therapy: Bispecific Antibodies Now Offered to Enhance Patient Outcomes first appeared on Daily Nurse.